The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•19 June 2026•

2 min read

BDX Faces Recall Pressure as Analysts Highlight Undervaluation for BDX and KDP Stocks

Key Facts

1Becton Dickinson initiated a voluntary Class I recall for its Spinal Tray products due to supplier testing deficiencies.

2Analysis suggests BDX stock could be 20.6% undervalued despite a 26.14% year-to-date decline.

3Keurig Dr Pepper trades at a slight discount to peers with a consensus price target of $33.53.

Amid rising operational challenges in the med-tech sector, Becton Dickinson has initiated a voluntary Class I recall for its Spinal Tray products due to supplier testing deficiencies. According to reports, this move coincides with analysis suggesting BDX stock could be 20.6% undervalued, despite a sharp 26.14% decline since the start of the year. Additionally, Keurig Dr Pepper is noted to be trading at a slight discount to its peers, with a consensus price target set at $33.53.

These shifts in the healthcare and consumer sectors occur as competitors show mixed performance; market data indicates relative stability in peers like Baxter International and Coca-Cola, a key rival for KDP in the beverage space. Compared to previous quarters, BDX is navigating the complexities of business separations, while investors watch KDP’s ability to expand margins despite commodity price volatility, with the stock currently trading near historical support levels per market data.

Traders should monitor current price levels, with BDX closing at $143.98 and KDP at $30.76 (close June 18, 2026). Looking ahead, upcoming global retail sales and consumer confidence data in the economic calendar could influence risk appetite across the beverage and medical equipment sectors. Markets will also be alert for any further FDA regulatory updates regarding the recall to assess the final financial impact on BDX.